William R. Davis

William R. Davis

Auto-generated profile, based on publicly available information

William R. Davis

The University of North Carolina School of Medicine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in JSES Reviews, Reports, and Techniques
Verified
Journal Article
Open access
WDWilliam R. Davis
William R. Davis
NBNicholas C. Bank
Nicholas C. Bank
BLBradley J Lauck
Bradley J Lauck
RCRobert A. Creighton
Robert A. Creighton
RMR. Justin Mistovich
R. Justin Mistovich
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for managing type 2 diabetes mellitus (T2DM) and obesity due to their proven metabolic benefits. However, their impact on musculoskeletal conditions, particularly in non-weight-bearing joints such as the shoulder joint, remains unclear. This study aimed to determine whether GLP-1RA use was associated with the development of shoulder pathologies (glenohumeral osteoarthritis, adhesive capsulitis, atraumatic rotator cuff tears, and shoulder fractures) over a 5-year period. A retrospective cohort study was performed using the TriNetX research database. Adult patients prescribed GLP-1RAs between 2017 and 2019 were identified and stratified into 3 cohorts based on obesity (body mass index ≥30) and T2DM status: (1) obese T2DM, (2) nonobese T2DM, and (3) nonobese non-T2DM. Within each group, GLP-1RA users were 1:1 propensity score matched to nonusers. Primary outcomes (glenohumeral osteoarthritis, adhesive capsulitis, atraumatic rotator cuff tears, and shoulder fractures) were evaluated over a 5-year period, and secondary outcomes (hemoglobin A1c and body mass index) were assessed over a 2-year period. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to compare incidence between GLP-1RA users and nonusers. At 5-year follow-up, GLP-1RA use was associated with higher incidence rates of glenohumeral osteoarthritis, adhesive capsulitis, and atraumatic rotator cuff tears across all subgroups as compared to nonusers. The highest increased risk was observed for adhesive capsulitis, particularly in the obese nondiabetic subgroup (HR: 2.465; 95% CI [3.173-1.916]). Shoulder fracture incidence was lower among GLP-1RA users with both obesity and T2DM (HR: 0.903; 95% CI [0.827-0.987]) but did not differ significantly in patients with obesity without T2DM or in nonobese patients with diabetes. GLP-1RA therapy was associated with an increased incidence of certain shoulder pathologies, most notably adhesive capsulitis, suggesting GLP-1RAs may have adverse musculoskeletal effects in the shoulder joint. These findings highlight the need for future prospective studies to confirm these associations.

30 May 2026 in Shoulder & Elbow
Verified
Journal Article
Open access
BLBradley J Lauck
Bradley J Lauck
NBNicholas C Bank
Nicholas C Bank
WDWilliam R Davis
William R Davis
CCCharles B Colson
Charles B Colson
SHStephen Himmelberg
Stephen Himmelberg
ARAlan W Reynolds
Alan W Reynolds
Background: Over the last decade, total shoulder arthroplasty (TSA) has increasingly transitioned to the outpatient setting, where postoperative care pathways inherently limit the ability to deliver a full 24 hour course of intravenous antibiotic prophylaxis. Despite guideline recommendations, extended oral antibiotic prophylaxis is variably used after outpatient TSA, with limited evidence supporting this practice. Methods: A retrospective cohort study using the TriNetX database identified patients undergoing primary outpatient TSA between 2015 and 2025. Patients were stratified by receipt of extended oral antibiotic prophylaxis. Propensity score matching yielded two cohorts of 2647 patients each. Outcomes included periprosthetic joint infection (PJI), surgical site infection (SSI), all-cause revision, wound disruption, and emergency department utilization at 90 days and 1 year. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Results: At 90 days, there were no significant differences in PJI (0.9% vs 0.5%; RR 1.20, 95% CI 0.96–3.84) or SSI (0.8% vs 0.5%; RR 1.67, 95% CI 0.82–3.40). At 1 year, PJI (1.6% vs 1.2%; RR 1.34, 95% CI 0.85–2.12) and SSI (1.1% vs 0.8%; RR 1.14, 95% CI 0.79–2.42) rates remained comparable between groups. Discussion: Extended oral antibiotic prophylaxis did not reduce infection-related outcomes following primary outpatient TSA. Level of evidence: III, Retrospective cohort study.

3 November 2026 in Arthritis & Rheumatology
Verified
Journal Article
Open access
MPMatheus Moreira Perez
Matheus Moreira Perez
PRPranay Ramteke
Pranay Ramteke
BWBahiyah Watson
Bahiyah Watson
OHOwen Haslam
Owen Haslam
ECEirene Choi
Eirene Choi
JCJohn A. Collins
John A. Collins
Objective: Sirtuin 6 (SIRT6) is a nuclear‐localized histone deacetylase that regulates multiple pathways associated with aging. This study aimed to determine whether systemic administration of MDL‐800, a small molecule activator of SIRT6, decreases the severity of age‐associated osteoarthritis (OA) in mice. Methods: Male, 18‐month‐old mice received weekly intraperitoneal injections of MDL‐800 or vehicle control for 6 months, and OA severity was assessed at 24 months using histology, micro–computed tomography, and histomorphometry. The role of MDL‐800–induced SIRT6 activation in human chondrocyte function was analyzed using RNA sequencing and immunoblotting. The effect of MDL‐800 to reduce DNA damage was assessed in human and mouse synovial fibroblasts by the comet assay. Results: Mice receiving long‐term administration of MDL‐800 were protected from OA pathology when compared to controls, as characterized by less cartilage damage, osteophyte formation, synovial hyperplasia, subchondral bone sclerosis, and meniscal ossification. RNA sequencing of chondrocytes revealed that MDL‐800 negatively enriched pathways associated with bone formation, angiogenesis, and catabolic MAPK signaling, while positively enriching pathways associated with epigenetic regulation, telomere maintenance, mitochondrial function, redox balance, and DNA repair. MDL‐800 significantly decreased oxidative stress‐induced phosphorylation of p38 in chondrocytes and basal DNA damage in human and mouse synovial fibroblasts. Conclusion: Activation of SIRT6 by MDL‐800 significantly protected old mice from age‐associated OA severity in vivo. MDL‐800 decreased pathways associated with pathologic bone formation and regulated multiple hallmarks of aging. Targeted therapies that activate SIRT6 may represent a novel strategy to repress multiple aging pathways to slow, stop, or reverse age‐associated OA.